Something else that hasn't been mentioned is the significant cost of running trials. Halving the patients will be a massive expenditure not needeed. While highly unlikely to halve the cost, it could potentially save us a quarter or even a third of the original forecast expense as compared to what it would have cost a week ago. I think our q4 books are going to look pretty good.
Something else that hasn't been mentioned is the significant...
- There are more pages in this discussion • 967 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.004(4.82%) |
Mkt cap ! $578.2M | |||
| Open | High | Low | Value | Volume |
| 8.2¢ | 8.3¢ | 7.7¢ | $1.357M | 17.06M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 735848 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 328052 | 7 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
8.0¢ |
Change
-0.004 ( 4.33 %) |
||||
| Open | High | Low | Volume | ||
| 8.2¢ | 8.2¢ | 7.8¢ | 7785002 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| IMU (ASX) Chart |